Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilematovir and Ciclosporin DDI Study in Healthy Adults
NCT05155007Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rilematovir in respiratory syncytial virus infection (RSV) (6 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Analyte Concentration of Rilematovir at 24 hours, Time to Reach Maximum Observed Plasma Analyte Concentration of Rilematovir at 24 hours and 4 more. Started Dec 2021; status: completed.
02
Drugs
rilematovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05155007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05155007.